Given that B7-H3 likely has a predominantly inhibitory role in anti-tumor immunity and may be a target in immunotherapy, clinical trials, including anti-B7-H3mAb only and combined with other approaches, have been initiated to determine the safety and efficacy of targeting B7-H3 in multiple cancer types 62. Here, CD80 is linked to neoplasm.